Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors.
Two hundred and eight acceptable patients were treated with Yoshi 864 (2 mg/kg/day by iv push X 5 days repeated once every 6 weeks). Toxicity was minimal. There was an overall response rate of 11%. Cross resistance with other alkylating agents may not be present. Because of its lack of toxicity, Yoshi 864 should be further evaluated in chronic myelocytic leukemia, lymphomas, and carcinomas of the ovary and bladder where significant responses were seen. It should also be evaluated in combinations as a replacement for other alkylating agents which cause more nausea and vomiting.
D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count; D008698:Mesylates / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000477:Alkylating Agents; D006454:Hemoglobins; D008698:Mesylates; D011437:Propylamines; C001441:improsan